A clinical study to determine the dose and assess safety and efficacy of radioimmuntherapy in patients with glioblastoma, where Lutetium 177 labelled 6A10 antibody Fab fragments are applied to the tumor resection cavity.

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513638-39-00

Acronym

UKM15_0027

Enrollment

Registered

2024-07-10

Start date

2022-10-17

Completion date

Unknown

Last updated

2026-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgically treated high grade glioma after concomitant radiochemotherapy and adjuvant standard chemotherapy, with no or small stable tumor residue

None listed

Sex/Gender

All

Age

18 Years to No maximum

Germany

None listed

Source: EU CTIS · Data processed: Feb 4, 2026